Rohto Pharmaceutical Co.,Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expected net sales of JPY 259,000 million, Operating profit of JPY 35,000 million, Profit attributable to owners of parent of JPY 26,500 million and Basic earnings per share of JPY 116.16.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,874 JPY | -0.55% | -8.65% | +1.09% |
Apr. 04 | Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen | MT |
Apr. 04 | Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.09% | 4.25B | |
+32.40% | 694B | |
+29.39% | 593B | |
-1.67% | 371B | |
+19.96% | 331B | |
+6.61% | 290B | |
+14.06% | 239B | |
-3.15% | 209B | |
+9.89% | 209B | |
+8.03% | 169B |
- Stock Market
- Equities
- 4527 Stock
- News Rohto Pharmaceutical Co.,Ltd.
- Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024